a Institute of Immunization and Prevention, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou , Zhejiang , China.
Hum Vaccin Immunother. 2018 Apr 3;14(4):1013-1017. doi: 10.1080/21645515.2017.1407481. Epub 2017 Dec 21.
To evaluate the initiation and completion and timeliness of inactivated hepatitis A vaccine (HAV-I) series, to identify the missed opportunities for HAV-I series, and to examine determinants associated with the completion of HAV-I.
Children born from 1 January 2005 to 31 December 2014 and registered in Zhejiang provincial immunization information system (ZJIIS), were enrolled in this study. Descriptive statistics were used to describe the initiation and completion, the timeliness and the missed opportunities for HAV-I. Logistic regression analysis was applied to explore the determinants of the completeness of HAV-I.
The initiation rate of HAV-I increased from 8.1% for the 2005 birth cohort to 13.2% for the 2014 birth cohort. The completion rate of HAV-I increased from 4.2% for the 2005 birth cohort to 7.8% for the 2014 birth cohort. The timeliness rate of the 1 dose of HAV-I increased from 38.2% for the 2005 birth cohort to 57.9% for the 2014 birth cohort. The timeliness rate the 2 dose of HAV-I increased from 17.3% for the 2005 birth cohort to 35.3% for the 2014 birth cohort. 78.3% of the children who did not initiated any hepatitis A vaccine, had at least one immunization clinic visit after their 18 month of age. 36.0% of the children who received the 1 dose of HAV-I but did not receive the 2 dose, had at least one immunization clinic visit after 6 months from the date of receiving the 1 dose of HAV-I. The determinants including year of birth, socio-economic development level of municipals, place of delivery, receipt of MMR/VarV were associated with the completion of HAV-I series.
Although the initiation and completion of HAV-I series had improved in recent years, these indicators were still lower than those for other vaccines scheduled at the similar age. It is important for providers to identify every opportunity for HAV-I vaccination and to assure that children get protection from this vaccine-preventable disease.
评估灭活甲型肝炎疫苗(HAV-I)系列的起始和完成情况以及及时性,确定 HAV-I 系列的遗漏机会,并研究与 HAV-I 完成情况相关的决定因素。
本研究纳入了 2005 年 1 月 1 日至 2014 年 12 月 31 日期间在浙江省免疫信息系统(ZJIIS)中注册的儿童。使用描述性统计方法描述 HAV-I 的起始和完成情况、及时性和遗漏机会。应用逻辑回归分析探讨 HAV-I 完全性的决定因素。
HAV-I 的起始率从 2005 年出生队列的 8.1%上升到 2014 年出生队列的 13.2%。HAV-I 的完成率从 2005 年出生队列的 4.2%上升到 2014 年出生队列的 7.8%。第 1 剂 HAV-I 的及时性率从 2005 年出生队列的 38.2%上升到 2014 年出生队列的 57.9%。第 2 剂 HAV-I 的及时性率从 2005 年出生队列的 17.3%上升到 2014 年出生队列的 35.3%。78.3%未接种任何甲型肝炎疫苗的儿童在 18 个月后至少有一次免疫接种门诊就诊。36.0%接受过 1 剂 HAV-I 但未接受 2 剂 HAV-I 的儿童在接种第 1 剂 HAV-I 后 6 个月内至少有一次免疫接种门诊就诊。出生年份、直辖市的社会经济发展水平、分娩地点、是否接种麻疹风疹联合疫苗(MMR/VarV)等因素与 HAV-I 系列的完成情况相关。
尽管近年来 HAV-I 系列的起始和完成情况有所改善,但这些指标仍低于其他同期安排的疫苗。提供者识别 HAV-I 疫苗接种的每个机会并确保儿童免受这种疫苗可预防疾病的影响非常重要。